

# GBA Task Force

Name	Company
<b>Richard Sun (Sponsor)</b>	<b>Abbvie</b>
<b>Dora Mo (Lead)</b>	<b>Takeda</b>
Kenny Lee	Abbvie
Ingrid Wong	Amgen
Hugo Tan	AstraZeneca
Kenny Lam	BMS
Danny Ko	DCH Auriga
Phoebe Mo	Kerry Pharma
Lewis Huen	Medinova
Stephen Lee	Merck
Michelle Ho	Novartis
Harry Fung	Roche

<b>Mission</b>	<ul style="list-style-type: none"> <li>Facilitate early expanded access of HK registered innovative medicines to patients in GBA</li> </ul>	
<b>Objective</b>	<ul style="list-style-type: none"> <li>Enhance the competitiveness and value proposition of HK, promote the city into one of the GBA's leading centre of excellence</li> <li>Develop a conducive business environment for the healthcare industries in GBA</li> </ul>	
<b>Endpoint</b>	I. Understand the market	II. The drug flow to GBA: logistics, pilot, Code of Practice
	<p><b>GBA training series to facilitate members' understanding on the GBA development</b></p> <ul style="list-style-type: none"> <li>Reinitiate the training programs post COVID19</li> <li>Virtual meetings</li> </ul>	<p><b>Implementation of the policy on allowing HK-registered drugs and medical devices in GBA</b></p> <ul style="list-style-type: none"> <li>Identify the approval process and drug lists</li> <li>Clarify the logistics arrangement of the pilot program of HKU-SZ hospital, <b>and to apply for the full access of GBA</b></li> <li>Clarify and set up clear code of practice</li> </ul>
<b>Future State</b>	<ul style="list-style-type: none"> <li>Broaden innovative medicine access to mainland Chinese patients</li> <li>Expand implementation to all HK owned healthcare institutions with successful pilot run by HKU-SZ Hospital</li> <li>Ensure proper medical education among relevant HCPs and treated patients on innovative medicines imported from HK</li> </ul>	